the aid library

LIST OPTIONS

Filter

4686

Sort by:

Direction:

Download (261)

View PDF (721)

Regional Ebola Preparedness Overview of Needs and Requirements June to December 2019
recommended

World Health Organization WHO (2019) C_WHO

This document presents a consolidated summary of urgent activities required to advance preparedness, as elaborated in each country's national plan, with a particular focus on Priority 1 countries. It presents the estimated requirements, needs, and gaps for each of the Priority 1 countries and a ... more

Download (594)

View PDF (996)

National Blood Policy

NACO, NBTC (2007)

Download (90)

View PDF (134)

Movilidad poblacional y VIH/sida en Centroamérica y México

R. Leyva-Flores; B. Aracena-Genao; E. Serván-Mori PAHO (Pan American Health Organization; World Health Organization); Rev Panam Salud Publica; Pan American Journal of Public Health (2014) C2

Investigación original / Original research Rev Panam Salud Publica 36(3), 2014

Download (1364)

View PDF (2995)

Ending Preventable Child Deaths from Pneumonia and Diarrhoea by 2025

World Health Organization; UNICEF (2013) C_WHO

The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD)

Download (87)

View PDF (240)

Trichiasis surgery for trachoma Second Edition

Merbs, S.; Resnikoff, S.; Kello, A. World Health Organization WHO (2015) C_WHO

This manual is designed to provide specific information for trachomatous trichiasis (TT) trainers who are training others to undertake surgery for entropion trachomatous trichiasis (TT). Other approaches are not addressed. The manual is divided into two parts. The first part covers specifics designe... more

Download (239)

View PDF (322)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more